Researchers explore the risks of cardiovascular and cerebrovascular events following vaccination against the COVID-19.
‘A Watershed Moment’: GLP-1 Drug Succeeds in Late-Stage MASH Trial
Semaglutide (Wegovy) improved liver fibrosis in patients with metabolic dysfunction-associated steatohepatitis (MASH) and led to greater rates of MASH resolution, an interim analysis of a